All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
EBMT 2018 | Retrospective analysis of the role of allo-SCT in PTCL
A lymphoma working party session took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 20 March 2018. Abstract WP7-6 won the Jian-jian Luan award for the best abstract in the topic of Lymphoma. The abstract presented by Anne-Claire Mamez, Hôpitaux Universitaires de Genève, Department of Hematology, Geneva on the role of allogeneic stem cell transplant (allo-SCT) use in patients with peripheral T-cell lymphoma (PTCL).
The retrospective analysis assessed PTCL patients who had allo-SCT between 2006 and 2014 using the Francophone Society of bone marrow transplantation and cellular therapy (SFGM)-TC database. Two-hundred and eighty-four patients were included in the study with a median age of 50 years (range, 16–69) were transplanted at a median of 12.6 months after diagnosis.
Patients received transplant as either first-line treatment (29%), after 2 lines (36%) and after ≥3 lines (35%). The speaker noted that 94% of patients had a Karnofsky performance status of above 80%. The donors for allo-SCT were either matched-related (45%), matched-unrelated (36%) or alternative (19%). Conditioning regimens given included: reduced intensity conditioning (RIC) n = 147, myeloablative (MAC) n = 106 and non-myeloablative (NMA) n = 27.
Key Findings
- Median follow-up = 33 months
- 1-year overall survival (OS) = 68% (95% CI, 0.62–0.7) and event-free survival (EFS) = 63% (95% CI, 0.57–0.69)
- 2-year OS = 64% (95% CI, 0.58–0.7) and EFS = 59% (95% CI, 0.53–0.65)
- 4-year OS = 57% (95% CI, 0.5–0.63)
- In a subgroup analysis of 30 patients with progressive disease, 50% achieved a complete response with a 2-year OS of 51%
- Median time to relapse = 94 days
- Non-relapse mortality = 22% (1-year) and 24% (2-year)
- Deaths occurred due to relapse (35%), infection (27%) and graft-versus-host-disease (GvHD; 22%)
- Grade II-IV GvHD was observed in 31% of patients
- Chronic GvHD occurred in 34%
The speaker concluded that according to the study findings at long term follow-up, grade ≥3 GvHD and low Karnofsky scores negatively impacted OS. Additionally, the conditioning regimen did not significantly influence OS.
References
Your opinion matters
On average, how many patients with chronic lymphocytic leukemia do you see in a month?